Pentixapharm Holding AG (ETR:PTP)

Market Cap	52.04M -28.8%
Revenue (ttm)	526.00K -74.4%
Net Income	-16.51M
EPS	-0.67
Shares Out	24.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,229
Average Volume	4,788
Open	2.030
Previous Close	2.030
Day's Range	2.030 - 2.150
52-Week Range	1.300 - 3.700
Beta	n/a
RSI	58.78
Earnings Date	Mar 26, 2026

About Pentixapharm Holding AG

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 ligand-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 61
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: PTP

Financial Performance

In 2025, Pentixapharm Holding AG's revenue was 526,000, a decrease of -74.37% compared to the previous year's 2.05 million. Losses were -16.51 million, 26.4% more than in 2024.